The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 28, 2020

Filed:

Dec. 10, 2019
Applicants:

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;

Baylor Research Institute, Dallas, TX (US);

Universite Paris Est Creteil Val DE Marne, Creteil, FR;

Assistance Publique Hopitaux DE Paris, Paris, FR;

Inventors:

Yves Levy, Paris, FR;

Gerard Zurawski, Midlothian, TX (US);

Sandra Zurawski, Midlothian, TX (US);

Anne-Laure Flamar, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 39/12 (2006.01); A61K 39/21 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C07K 16/10 (2006.01); A61P 31/18 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 39/12 (2013.01); A61P 31/18 (2018.01); C07K 14/005 (2013.01); C07K 16/1063 (2013.01); C07K 16/28 (2013.01); C07K 16/2878 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6056 (2013.01); A61K 2039/627 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/40 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16171 (2013.01);
Abstract

Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).


Find Patent Forward Citations

Loading…